FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases
NCT ID: NCT04832776
Last Updated: 2021-04-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
160 participants
INTERVENTIONAL
2021-04-17
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM
NCT03493048
mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases
NCT04781270
Study of Cetuximab in Combination With mFOLFOX-6 (Oxaliplatin, Leucovorin, 5-FU) to Treat Colorectal Liver Metastatic Cancer Patients
NCT01322178
Pattern of Use of Bevacizumab or Cetuximab + FOLFIRI Regimen as First-line Treatment in Metastatic Colorectal Cancer
NCT03286738
Postoperative Folfox4 Only Versus Folfox4 Plus Transhepatic Arterial Chemotherapy (TAC) in the Treatment Unresectable Liver Metastasis of Colorectal Cancer
NCT00869271
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
FOLFOXIRI+C225
Cetuximab
one group plus cetuximab
FOLFOXIRI
FOLFOXIRI
FOLFOXIRI+BEV
Bevacizumab
one group plus bevacizumab
FOLFOXIRI
FOLFOXIRI
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cetuximab
one group plus cetuximab
Bevacizumab
one group plus bevacizumab
FOLFOXIRI
FOLFOXIRI
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* pathologically confirmed colorectal carcinoma, with RAS wild type
* inital unresectable liver metastases discussed by MDT
* prior no systemical therapy or exceed 6 months after the adjuvant chemotherapy of primary tumor surgery.
* without extraheptic metastatic lesions, except for locally controlled lung metastases (RFA or SBRT)
* adequate blood, liver and renal function
* expected survival longer than 6 months
Exclusion Criteria
* interestinal obstruction or disease
* uncontrolled hypertension and severe heart disease
* previous severe thrombotic events
* central nervous system metastases
* accompanied with other malignant tumor
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fudan University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sanjun Cai
Department of Colorectal Surgery
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wen Zhang
Role: PRINCIPAL_INVESTIGATOR
Fudan University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Colorectal Surgery Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Cetu-Bev-FOLFOXIRI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.